UnitedHealth Q2 Preview: Revenue Growth Expected, But Investor Worries Persist

UnitedHealth ($UNH) is scheduled to report its Q2 earnings this Tuesday, July 29, before the market opens.

Analysts are expecting a 13.2% year-over-year increase in revenue to around $111.9 billion, with adjusted earnings per share projected at $4.49, down 34% year over year.

While topline growth looks solid on paper, investors are bracing for another tough quarter as the company continues to grapple with higher medical costs, regulatory scrutiny, and ongoing leadership uncertainty.

Strong Sector Trends, But UNH Faces Company-Specific Headwinds

Peers in the health insurance space have posted strong Q2 results—Centene grew revenue 22.4% YoY, beating estimates by over 11%, and Molina Healthcare came in with 15.7% growth. These results suggest robust sector-level demand, likely supported by continued Medicaid and Medicare enrollment, especially after pandemic-era protections expired.

UnitedHealth also reported solid enrollment trends last quarter, adding 395,000 customers to reach 54.12 million members. Analysts expect this momentum to continue, helped in part by growth in the company’s Optum division and home healthcare offerings.

That said, UNH’s first quarter was far from perfect—it missed revenue expectations by 1.7% and saw its medical care ratio (MCR) rise to 84.8%, reflecting higher care utilization, particularly among seniors. This puts added pressure on the company to deliver improved profitability metrics this quarter.

This quarter, investors will closely monitor whether MCR pressures persist, and whether UnitedHealth can rein in operating costs after improving its operating cost ratio to 12.4% in Q1.

DOJ Probe Casts a Shadow Over HouseCalls Program

One major overhang heading into earnings is the formal DOJ investigation into UnitedHealth’s Medicare billing practices.

At the center of this probe is the company’s HouseCalls program, which sends clinicians to patients’ homes. Former employees allege the program was designed to capture higher-paying diagnoses while reducing hospital transfers, which critics say may have delayed critical care.

UnitedHealth has pushed back on these claims, calling them “verifiably false,” and says it’s cooperating fully with both civil and criminal investigations.

While some analysts, like J.P. Morgan’s Lisa Gill, view this as part of a broader industry trend and remain constructive on the stock, others have grown more cautious.

Deutsche Bank and Leerink Partners both lowered their price targets in recent weeks, although both still maintain Buy ratings. Deutsche’s George Hill pointed to deteriorating investor sentiment, especially around Optum Health, while Leerink’s Whit Mayo remains “cautiously optimistic.”

Stock Down 44% YTD, But Analysts Still See Upside

Despite a steep 44.44% year-to-date drop, UNH still holds a Moderate Buy rating from Wall Street, based on 18 Buys, 5 Holds, and 1 Sell over the past three months. The average price target of $348.12 implies 23.86% upside from current levels.

Options markets are pricing in a nearly 8% move following the earnings announcement, reflecting elevated uncertainty.

What to Watch on Tuesday

Medical care ratio (MCR): Did utilization pressures ease?
Optum’s performance: Any sign of stabilization or improvement?
Management commentary: Updates on the DOJ probe, the $1B Banmedica sale, and forward guidance.
EPS trend: Analysts expect a 34% drop YoY—can UNH beat the lowered bar and stabilize investor sentiment?

Bottom Line

UnitedHealth is still a heavyweight in the health insurance industry, and long-term fundamentals—like population aging and Medicare Advantage growth—remain supportive. But with rising regulatory pressure, elevated costs, and CEO turnover, it’s clear the company is in a transitional phase.

Tuesday’s report may not provide all the answers, but it will likely shape the near-term sentiment around UNH as it works to rebuild investor confidence.

What’s Your Estimate?

While investors wait to see if UnitedHealth’s Q2 numbers will confirm a shift in momentum, there's another way to get involved: our app is running a bounty challenge — predict the stock's percentage change range for the trading day following the earnings release.

👉 [Join the challenge here]